2/12
07:30 am
lyel
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
Low
Report
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
12/24
08:31 am
lyel
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]
Low
Report
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data [Seeking Alpha]
12/17
11:01 am
lyel
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]
Medium
Report
Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain [Yahoo! Finance]
12/9
07:01 am
lyel
Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
Medium
Report
Lyell Immunopharma (NASDAQ:LYEL) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.
12/7
04:30 pm
lyel
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
High
Report
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
11/24
07:19 am
lyel
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.